La cadena de opciones muestra datos clave de las opciones de acciones de Outlook Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Outlook Therapeutics..

Outlook Therapeutics (NASDAQ:OTLK) Bolsa, Cadena de Opciones

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

U.S. President&nbsp;Donald Trump&nbsp;has demanded that iPhones sold in the U.S. be manufactured domestically, threatening a 25% tariff on&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) otherwise.
What Happened: On Friday, Trump took to his Truth Social to reiterate his expectations to Apple&#8217;s CEO, Tim Cook, that iPhones sold in the U.S. should be &#8220;manufactured and built&#8221; domestically and not in India. 
He warned of a substantial tariff of &#8220;at least 25%&#8221; if this is not the case.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="609" height="257" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23073341/Screenshot-2025-05-23-170302.png" alt="" class="wp-image-925868" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23073341/Screenshot-2025-05-23-170302.png 609w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23073341/Screenshot-2025-05-23-170302-300x127.png 300w" sizes="(max-width: 609px) 100vw, 609px" /></figure>
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45581129/trump-gala-dinner-saw-president-wine-and-dine-top-memecoin-holders-as-protestors-flashed-don-the-con-signs-exclusive" target="_blank" rel="noreferrer noopener">Trump Gala Dinner Saw President Wine And Dine Top Memecoin Holders As Protestors Flashed &#8216;Don The Con&#8217; Signs — Exclusive &#8211; Benzinga</a>
Why It Matters: This came after Apple reportedly plans to ramp up its presence in India by expanding its supply chain operations through its leading manufacturing partner, Foxconn, officially known as Hon Hai Precision Industry Co. Ltd. (OTCPK: HNHAF). Foxconn plans to <a href="https://www.benzinga.com/news/global/25/05/45582261/despite-trumps-warning-to-tim-cook-apple-moves-ahead-with-1-5-billion-india-expansion-via-foxconn-to-boost-iphone-production-report">invest $1.5 billion</a> in a new display module plant near Chennai, India, assembling screen components for iPhones.
Despite Trump&#8217;s criticism, India, earlier, said it remains committed to its growing partnership with Apple. The Tim Cook-led company has reassured the Indian government of its commitment to continue using India as a major manufacturing base. This assurance comes despite Trump's recent remarks, with government sources emphasizing that there is "<a href="https://www.benzinga.com/markets/25/05/45462006/no-change-in-apples-production-plans-says-india-despite-trumps-little-problem-with-ceo-tim-cook-report">no change</a>" in Apple's investment plans in India.
Price Action: Apple shares dipped over 3% during Friday&#8217;s premarket session, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Benzinga Edge Stock Rankings assigned Apple a growth score of 33.12%. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Click here to compare it with other major players</a>. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener"></a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23075059/Screenshot-2025-05-23-at-9.44.36%E2%80%AFAM-1-1.png" alt="" class="wp-image-925885" /></a></figure>
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45581297/trumps-big-beautiful-3-8-trillion-bill-squeaks-through-house-expert-says-it-will-boost-the-economy-in-the-sh" target="_blank" rel="noreferrer noopener">Trump&#8217;s &#8216;Big, Beautiful&#8217; $3.8 Trillion Bill Squeaks Through House: Expert Says It Will &#8216;Boost The Economy In The Short Term,&#8217; But Worsen Deficits</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AAPL

HNHAF

Trump Threatens Tim Cook To Manufacture iPhones In US Or Face 'At Least 25%' Tariffs: AAPL Stock Slides Over 3% In Premarket

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower after President Trump recommended a 50% straight tariff on the European Union, staring Jun. 1

<a href="https://truthsocial.com/@realDonaldTrump/posts/114556968834547173" title="https://truthsocial.com/@realDonaldTrump/posts/114556968834547173">https://truthsocial.com/@realDonaldTrump/posts/114556968834547173</a>

Macro Economic Events

Macro Notification

Global

Economics

General

President Trump Recommends Straight 50% Tariff On EU, Starting Jun. 1

Telsey Advisory Group analyst Dana Telsey maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and maintains $315 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Ralph Lauren, Maintains $315 Price Target

Apple shares are trading lower after President Trump said he told CEO Tim Cook he expects iPhones sold in the US will be manufactured and built in the US. Trump said company must pay a 25% tariff if this is not the case.

Telsey Advisory Group analyst Dana Telsey maintains Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) with a Market Perform and maintains $150 price target.

ROST

Telsey Advisory Group Maintains Market Perform on Ross Stores, Maintains $150 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and maintains $460 price target.

ULTA

Telsey Advisory Group Maintains Outperform on Ulta Beauty, Maintains $460 Price Target

U.S. President Donald Trump's Golden Dome missile defense system could usher in a new era of space-based weaponry.
What Happened: The Trump administration's Golden Dome could provoke other states to employ similar systems in space and fast-track the militarization of space, experts suggest in a report published by Reuters on Thursday.
"I think it&#8217;s opening a Pandora&#8217;s box. We haven&#8217;t truly thought about the long-term consequences for doing so,&#8221; an expert cited in the report said.
Experts aren't the only ones expressing concerns as a spokesperson for the Kremlin suggested that developing such a system could trigger talks about nuclear arms control between the U.S. and Russia in the foreseeable future, the report added.&nbsp;
Talks of an orbital defense system aren't new as former U.S. President Ronald Reagan had first suggested the idea in his initiative dubbed the "Star Wars" Program, which Reagan said would render Nuclear weapons Obsolete.&nbsp;
Trump administration's plans to revive talks of a space-based arsenal of weapons come alongside a growing number of states across the globe increasing their nuclear capabilities.
Why It Matters: Several of the U.S. top tech and defense companies are pitching to work closely with the Trump administration to develop the Golden Dome defense system. Reports suggest that Elon Musk's SpaceX as well as Peter Thiel&#8217;s Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), have <a href="https://www.benzinga.com/25/04/44861620/spacex-palantir-frontrunners-in-bid-that-could-build-donald-trumps-golden-dome-report">emerged as frontrunners</a> in the project.
Defense contractor L3 Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) has also <a href="https://www.benzinga.com/25/05/45548110/trumps-golden-dome-launches-new-era-for-defense-stocks-like-rtx-lockheed-martin-l3harris">emerged as a key player </a>in the system's development and will manufacture satellites for the system. Investment bank Goldman Sachs says the company will be among the <a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">biggest corporate winners</a> following the initiative.
However, Xi Jinping's CCP has <a href="https://www.benzinga.com/markets/25/05/45541866/xi-jinpings-china-wants-trump-to-immediately-drop-the-golden-dome-project-over-strong-offensive-implications-security-of-all-countries-should-not-be-compromised">expressed serious concerns</a> about the project's development and has urged the Trump administration to reconsider the initiative as a whole.&nbsp;
Mao Ning, a spokesperson for the Chinese Foreign Ministry, said, "The United States, in pursuing a ‘U.S.-first' policy, is obsessed with seeking absolute security for itself. This violates the principle that the security of all countries should not be compromised."
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44859234/vladimir-putin-hails-elon-musk-comparing-him-to-soviet-space-program-pioneer-such-people-rarely-appear-in-the-human-population">Vladimir Putin Hails Elon Musk, Compares Him To Soviet Space Program Pioneer: ‘Such People Rarely Appear In The Human Population'</a></li>
</ul>
Image Via Shutterstock

SPACE

Politics

PLTR

Donald Trump's $175 Billion Golden Dome Could Trigger A New Space Arms Race, Expert Warns: '...It's Opening A Pandora's Box'

Altisource Portfolio Solutions S.A. ("Altisource" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>), a leading provider and marketplace for the real estate and mortgage industries, today announced that it will effect a consolidation of its shares (also known as a reverse stock split) at a ratio of 1-for-8, effective as of 12:01 a.m. CET on May 28, 2025 (the "Share Consolidation").
Altisource's common stock will begin trading on The Nasdaq Global Select Market on a Share Consolidation-adjusted basis at the opening of the market on May 28, 2025. Following the Share Consolidation, Altisource's common stock will continue to trade on The Nasdaq Global Select Market under the symbol "ASPS" with the new CUSIP number, L0175J 138. The Share Consolidation is intended to allow Altisource to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Global Select Market.
The Share Consolidation will reduce the number of issued and outstanding shares of Altisource's common stock from approximately 88,951,925 to approximately 11,118,990.
Altisource's board of directors approved the Share Consolidation on March 16, 2025. At Altisource's Extraordinary General Meeting of Shareholders held on May 13, 2025, Altisource's shareholders approved the Share Consolidation with effect as of May 28, 2025.

Stock Split

ASPS

Altisource To Effect Consolidation Of Shares At Ratio Of 1-For-8, Effective As Of 12:01 A.M. CET On May 28, 2025

Crypto markets are trading sideways on Friday morning as the fear and greed index continues to extend into the &#8216;extreme greed&#8217; zone.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$111,032.03</td>
<td>+0.22%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,662.21</td>
<td>+0.65%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$185.24</td>
<td>+4.2%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.43</td>
<td>+0.96%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2451</td>
<td>+2.4%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001552</td>
<td>+1.9%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume increased by 26.2% and 4.6%, respectively. BTC's daily active addresses are up by 5.8%.</li>
<li>Coinglass data shows 103,711 traders were liquidated in the past 24 hours for $247.61 million. </li>
<li>SoSoValue data shows $934.7 million in net inflows into spot Bitcoin ETFs and $110.5 million net inflows into spot Ethereum ETFs.</li>
</ul>
Trader Notes: Michael van de Poppe <a href="https://x.com/CryptoMichNL/status/1925821278327378178">sees</a> the $105,000–$108,000 zone as a prime buy-the-dip opportunity for BTC and altcoins, stating the real bull market is now underway.
CrediBULL Crypto <a href="https://x.com/CredibleCrypto/status/1925644215700095260">believes</a> Bitcoin's impulsive breakout confirms his January thesis, forecasting a massive altcoin rally ahead. 
Daan Crypto Trades points to $110,000 and $112,000 as critical breakout levels for Bitcoin, noting BTC's unusually steady price action near all-time highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Over a day and still near the middle of the range. Very uncommon to see this at all time highs. Keep a close eye on the $110K &amp; $112K levels as a big move is likely to occur from breaking either side of those. <a href="https://t.co/FudGTMl5fR">https://t.co/FudGTMl5fR</a> <a href="https://t.co/t4aDkLEq2O">pic.twitter.com/t4aDkLEq2O</a>
&mdash; Daan Crypto Trades (@DaanCrypto) <a href="https://twitter.com/DaanCrypto/status/1925841109478977582?ref_src=twsrc%5Etfw">May 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cold Blooded Shiller <a href="https://x.com/ColdBloodShill/status/1925836811982590094">sees</a> Solana nearing a breakout from its 4-month downtrend, urging traders not to assume they've missed the move.
Trader Tardigrade believes Dogecoin is on the verge of breaking recent highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> is likely to break the recent high &#x1f525;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/HG6zj8zWCI">pic.twitter.com/HG6zj8zWCI</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1925862535556681830?ref_src=twsrc%5Etfw">May 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Pentoshi highlights Ethereum approaching the $2,800s. A clean flip could open the door to $3,300, but first it needs to hold that zone.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> Getting closer for its move towards 28xx, flip that opens a potentially big move into 3.3k But first, lets get there <a href="https://t.co/mLcgTKQsQ5">https://t.co/mLcgTKQsQ5</a> <a href="https://t.co/p9UuABtFvs">pic.twitter.com/p9UuABtFvs</a>
&mdash; &#x1f427; Pentoshi (@Pentosh1) <a href="https://twitter.com/Pentosh1/status/1925727298856132753?ref_src=twsrc%5Etfw">May 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a style="font-weight: bold;" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45568207/bitcoin-to-120000-next-heres-what-technical-analysis-says">Bitcoin To $120,000 Next? Here&#8217;s What Technical Analysis Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP Steady, Dogecoin Climbs: Watch These Levels, Traders Caution

<a href="https://truthsocial.com/@realDonaldTrump/posts/114556874484491575" title="https://truthsocial.com/@realDonaldTrump/posts/114556874484491575">https://truthsocial.com/@realDonaldTrump/posts/114556874484491575</a>
<a href="https://truthsocial.com/@realDonaldTrump/posts/114556874484491575" title="https://truthsocial.com/@realDonaldTrump/posts/114556874484491575">https://truthsocial.com/@realDonaldTrump/posts/114556874484491575</a>

Movers

Apple Shares Lower Premarket After President Trump Says 'I have long ago informed Tim Cook of Apple that I expect their iPhone's that will be sold in the United  States of America will be manufactured and built in the United States, not India, or anyplace else. If that is not the case, a Tariff of at least 25% must be paid by Apple to the U.S. Thank your for your attention to this matter!'

Wedbush analyst Daniel Ives maintains Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) with a Outperform and raises the price target from $45 to $55.

OKLO

Wedbush Maintains Outperform on Oklo, Raises Price Target to $55

Wolfe Research analyst Andrew Rosivach upgrades Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) from Peer Perform to Outperform.

Upgrades

NMRK

Wolfe Research Upgrades Newmark Group to Outperform

D. Boral Capital analyst Jesse Sobelson maintains EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) with a Buy and maintains $2 price target.

EONR

D. Boral Capital Maintains Buy on EON Resources, Maintains $2 Price Target

Barrington Research analyst Patrick Sholl maintains Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) with a Outperform and maintains $25 price target.

Barrington Research Maintains Outperform on Marcus, Maintains $25 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Outperform and lowers the price target from $100 to $90.

Telsey Advisory Group Maintains Outperform on Best Buy Co, Lowers Price Target to $90

<ul>
<li>Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuations</li>
<li>Successful completion of the pivotal Phase 3 study may support Biologics License Application, Priority Review, Full Approval, and Commercialization</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ)), (TSX:<a href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the presentation of positive survival and clinical benefit data in three clinical poster presentations and one publish-only abstract at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.

BCTX

BriaCell Therapeutics To Highlight Survival And Clinical Benefit Data In Three Clinical Poster Presentations And One Publish-Only Abstract At 2025 ASCO Annual Meeting

Telsey Advisory Group analyst Dana Telsey downgrades Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) from Outperform to Market Perform and lowers the price target from $240 to $120.

Downgrades

DECK

Telsey Advisory Group Downgrades Deckers Outdoor to Market Perform, Lowers Price Target to $120

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $340 to $345.

ADSK

Rosenblatt Maintains Buy on Autodesk, Raises Price Target to $345

Rosenblatt analyst Kevin Cassidy maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and maintains $130 price target.

Rosenblatt Maintains Buy on Seagate Tech Hldgs, Maintains $130 Price Target

Management

Press Releases

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Participates in Virtual Investor "What This Means" Segment

Earnings

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Events

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

Outlook Therapeutics® Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Health Care

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

IPOs

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

AKTX

AMIX

AREC

CNSP

HURA

NVNO

PALI

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Biomea Fusion

Celularity

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

Immuneering Corporation - Class A Common Stock

Immuneering

Opus Genetics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MAIA Biotechnology

Metagenomi

OKYO Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Renovaro

Repare Therapeutics

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

Comments

Outlook Therapeutics

Outlook Therapeutics (OTLK) Opciones

Outlook Therapeutics (NASDAQ:OTLK) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL